Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.74 |
| ▸ | PNMT | P11086 | 2/20 | 0.63 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8772436 | 0.98 | TAAR1 (0.71) | TAAR1PNMTIDO1MAOACYP1A2 | |
| SCHEMBL10914706 | 0.94 | TAAR1 (0.77) | TAAR1PNMTIDO1CYP1A2CYP2D6 | |
| SCHEMBL1570973 | 0.85 | TAAR1 (1.00) | TAAR1PNMTIDO1CYP1A2CYP2D6 | |
| SCHEMBL30785390 | 0.85 | TAAR1 (1.00) | TAAR1PNMTIDO1CYP1A2CYP2D6 | |
| SCHEMBL3788445 | 0.83 | TAAR1 (0.72) | TAAR1PNMTIDO1MAOACYP1A2 | |
| SCHEMBL5105858 | 0.82 | TAAR1 (0.65) | TAAR1PNMTIDO1CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL28508673 | 0.82 | TAAR1 (0.69) | TAAR1PNMTIDO1MAOACYP1A2 | |
| SCHEMBL6680624 | 0.80 | TAAR1 (0.57) | TAAR1PNMTIDO1KDM4EALDH1A1 | |
| SCHEMBL29025294 | 0.80 | TAAR1 (0.57) | TAAR1PNMTIDO1CYP1A2CYP2D6 | |
| SCHEMBL5701276 | 0.78 | TAAR1 (0.55) | TAAR1PNMTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486985-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110136884-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2319511-A2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | Allergan, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136884-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | TAAR1 77/4885PNMT 195/4885IDO1 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.